NCT03087708 2025-07-17
Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
Clinical Trials
12 trialsNCT03720613 2025-02-12
Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation
BioDelivery Sciences International
Recruiting
NCT03638440 2024-06-17
NACASY
Kyowa Kirin Co., Ltd.
Completed
NCT04294550 2022-02-28
Study on Quality of Life in Advanced Cancer Patients With Opioid-induced Constipation Treated With Naloxegol
Fondazione ANT Italia ONLUS
Completed
NCT04219046 2020-07-28
ANTAGOCYST
Institut Paoli-Calmettes
Phase 2 Unknown
NCT02745353 2019-12-09
Naloxegol in Cancer Opioid-Induced Constipation
University of California, San Diego
Phase 2 Terminated
NCT02839889 2019-03-05
Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)
Hospice of Henderson County, Inc.
Phase 4 Terminated
NCT01395524 2017-02-23
A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation
AstraZeneca
Phase 3 Completed
NCT01323790 2015-06-02
Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
AstraZeneca
Phase 3 Completed
NCT01309841 2015-06-01
Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
AstraZeneca
Phase 3 Completed
NCT01384292 2015-06-01
Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain
AstraZeneca
Phase 3 Terminated
NCT01336205 2014-10-20
Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
AstraZeneca
Phase 3 Completed